Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to -$618168.0.

  • Dare Bioscience's Change in Accured Expenses fell 48718.99% to -$618168.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $722383.0, marking a year-over-year increase of 12117.4%. This contributed to the annual value of $520816.0 for FY2024, which is 10629.6% up from last year.
  • Per Dare Bioscience's latest filing, its Change in Accured Expenses stood at -$618168.0 for Q3 2025, which was down 48718.99% from $695961.0 recorded in Q2 2025.
  • In the past 5 years, Dare Bioscience's Change in Accured Expenses ranged from a high of $6.8 million in Q4 2022 and a low of -$5.4 million during Q1 2023
  • Its 5-year average for Change in Accured Expenses is -$55037.9, with a median of -$418156.0 in 2021.
  • Per our database at Business Quant, Dare Bioscience's Change in Accured Expenses surged by 380929.94% in 2021 and then tumbled by 144801.76% in 2023.
  • Quarter analysis of 5 years shows Dare Bioscience's Change in Accured Expenses stood at -$640500.0 in 2021, then surged by 1155.06% to $6.8 million in 2022, then plummeted by 132.61% to -$2.2 million in 2023, then soared by 178.44% to $1.7 million in 2024, then plummeted by 135.76% to -$618168.0 in 2025.
  • Its Change in Accured Expenses stands at -$618168.0 for Q3 2025, versus $695961.0 for Q2 2025 and -$1.1 million for Q1 2025.